Skip to content
value.today
Immuneering Corp logo

Immuneering Corp

Total raised
$72 M
3 rounds on record
Latest round
$37 M
Dec 2020
First round on record
Sep 2019
Today
Went public
See the company page

Immuneering Corp is listed today as Immuneering Corporation: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Immuneering Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2025$25 MPrivate placement after listing$10 to $50 million

Immuneering Corp: Private sale, Aug 2025

Investors in this round

9 investors had bought by the notice of Sep 9, 2025: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Immuneering Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Benjamin J. Zeskind · Executive Officer, Director
  • Diana F. Hausman · Director
  • Laurie B. Keating · Director
  • Peter J. Feinberg · Director
  • Robert J. Carpenter · Director
  • Thomas J. Schall · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Benjamin J. Zeskind, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 9, 2025. Read the notice at the SEC.

equity, optionsSEC
Dec 2020$37 MNo. 3$10 to $50 million

Immuneering Corp: Raise no. 3, Dec 2020

Investors in this round

39 investors had bought by the notice of Jan 5, 2021: 39 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Immuneering Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$37 M of $62 M offered; $25 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Benjamin J. Zeskind · Executive Officer, Director
  • Andrew J. Phillips · Director
  • Joseph J. Kekst · Director
  • Robert J. Carpenter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Benjamin J. Zeskind, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 5, 2021. Read the notice at the SEC.

equitySEC
Jan 2020$20 MNo. 2$10 to $50 million

Immuneering Corp: Raise no. 2, Jan 2020

Investors in this round

67 investors had bought by the notice of Jan 27, 2020: 67 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Immuneering Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Benjamin J. Zeskind · Executive Officer, Director
  • Joseph J. Kekst · Director
  • Robert J. Carpenter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Benjamin Zeskind, President. Source: SEC Form D, newest notice filed Jan 27, 2020. Read the notice at the SEC.

equitySEC
Sep 2019$15 MNo. 1$10 to $50 million

Immuneering Corp: Raise no. 1, Sep 2019

Investors in this round

49 investors had bought by the notice of Oct 4, 2019: 49 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Immuneering Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Benjamin J. Zeskind · Executive Officer, Director
  • Robert J. Carpenter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Benjamin J. Zeskind, President. Source: SEC Form D, newest notice filed Oct 4, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Immuneering Corp chose not to state its revenue in its newest notice of a funding round (Sep 2025).

    SEC Form D · Sep 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Sep 2025

That is all the official record says: Immuneering Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Immuneering Corp are on record.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Immuneering Corp
InvestorKindAmountRoundRoleSource
Benjamin J. ZeskindPersonnot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Biren AminPersonnot statednot statedHeld Series B preferred stock (Form 3, 2021)SEC Form 3
Brett Matthew HallPersonnot statednot statedHeld Series A and B preferred stock (Form 3, 2021)SEC Form 3
Cormorant Asset Management, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Global Healthcare Master Fund, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Private Healthcare Fund III LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Robert J. CarpenterPersonnot statednot statedHeld Series A and B preferred stock, director (Form 3, 2021)SEC Form 3
Scott BarrettPersonnot statednot statedHeld Series A and B preferred stock (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 67 investors.

Largest shareholders today

Institutions holding Immuneering Corporation shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Immuneering Corp
NameRoleNamed in
Benjamin J. ZeskindExecutive officerSep 2025
Benjamin J. ZeskindDirectorSep 2025
Diana F. HausmanDirectorSep 2025
Laurie B. KeatingDirectorSep 2025
Peter J. FeinbergDirectorSep 2025
Robert J. CarpenterDirectorSep 2025
Thomas J. SchallDirectorSep 2025
Andrew J. PhillipsDirectorJan 2021
Joseph J. KekstDirectorJan 2021

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.